BioSpace News Archive

First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four leading clinical centers in the U.S. and Brazil

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has met with the US Food and Drug Administration (FDA) to discuss proposed resolutions for the deficiencies identified in the Complete Response Letter

Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the launch of its new corporate brand identity as part of its transformational efforts to rapidly innovate leading-edge products and services that enable, enhance and extend every breath.

Legacy, the premier digital fertility clinic for men, announced $10M in Series A fundraising led by FirstMark Capital.

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) to Gilead Sciences, Inc. (Nasdaq: GILD),

Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced that Joan Mannick , MD, Head of Research and Development, will participate in the 5 th Stanford Drug Discovery Symposium (SDDS 2021) being held virtually on April 19-20, 2021 .

March of Dimes, the nation’s leading nonprofit fighting for the health of moms and babies, announced that Covis Pharma Group is joining the effort. Covis Pharma will be the Presenting Sponsor at all March of Dimes events in Massachusetts in 2021 and 2022, including the Massachusetts March for Babies, the Lawn Party, the Black Ties for Babies Gala, the Signature Chef’s Event, and the Falmouth Road Race. “This partnership will have a major imp